Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 2313.

DOI: https://doi.org/10.1182/blood-2021-146796

Published: 2021

Journal Articles

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)

Blood (2021) 138 (Supplement 1): 2344.

DOI: https://doi.org/10.1182/blood-2021-147769

Published: 2021

Journal Articles

Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 4457.

DOI: https://doi.org/10.1182/blood-2021-149960

Published: 2021

Journal Articles

Genomic Analysis of NPM1 Mutation and KMT2A ( MLL )-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 4460.

DOI: https://doi.org/10.1182/blood-2021-149425

Published: 2021

Journal Articles

Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 4464.

DOI: https://doi.org/10.1182/blood-2021-148492

Published: 2021

Journal Articles

Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis

Blood (2021) 138 (Supplement 1): 4447.

DOI: https://doi.org/10.1182/blood-2021-149801

Published: 2021

Journal Articles

Genomic Analysis of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Blood (2020) 136 (Supplement 1): 32–34.

DOI: https://doi.org/10.1182/blood-2020-137343

Published: 2020

Journal Articles

Combination of Highly Sensitive C-Reactive Protein with R-ISS Is a Novel and Powerful Staging System in Multiple Myeloma

Miyuki Okura, MD, Naoko Ida, MD, Saki Tanaka, Takahiro Yamauchi, MD PhD

Blood (2020) 136 (Supplement 1): 7–8.

DOI: https://doi.org/10.1182/blood-2020-141200

Published: 2020

Journal Articles

Interim Analysis of Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study of Patients with AML

Blood (2020) 136 (Supplement 1): 2–3.

DOI: https://doi.org/10.1182/blood-2020-139147

Published: 2020

Journal Articles

Genetic Features of AML with MLL-Rearrangement and NPM1 Mutation: An Interim-Analysis of HM-Screen-Japan 01

SungGi Chi, MD PhD, Naoko Hosono, MD PhD, Takahiro Yamauchi, MD PhD, Kentaro Fukushima, MD, Hirohiko Shibayama, MD PhD, Seiichiro Katagiri, MDPhD, Akihiko Gotoh, MD PhD, Motohito Okabe, MD, Takanobu Morishita, MD, PhD, Masamitsu Yanada, MD PhD, Kazuhito Yamamoto, MD PhD, Naohito Fujishima, MD PhD, Naoto Takahashi, MD PhD, Reiki Ogasawara, MDPhD, Takeshi Kondo, MD PhD, Yoshikazu Utsu, MD PhD, Nobuyuki Aotsuka, MD, Yoshimasa Kamoda, MD, Kensuke Usuki, MD PhD, Kanenari Takemura, MD, Yasuyuki Nagata, MD PhD, Takaaki Ono, MD PhD, Tsutomu Kobayashi, MD PhD, Junya Kuroda, MD PhD, Hiroto Horiguchi, MDPhD, Satoshi Iyama, MD PhD, Suguru Fukuhara, MD PhD, Koji Izutsu, MD PhD, Makoto Nakamura, MD PhD, Kazuto Togitani, MD, Kensuke Kojima, MD PhD, Kaoru Yamamoto, MD, Yukinori Nakamura, MD, Makoto Yoshimitsu, MD PhD, Kenji Ishitsuka, MD PhD, Kenichi Miyamoto, MD, Yosuke Minami, MDPhD

Blood (2020) 136 (Supplement 1): 35–36.

DOI: https://doi.org/10.1182/blood-2020-139240

Published: 2020

Journal Articles

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Blood (2020) 135 (24): 2137–2145.

DOI: https://doi.org/10.1182/blood.2020004856

Published: 2020

Includes: Supplemental data

Journal Articles

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Shinya Rai, MD PhD, Koji Kato, MD PhD, Junji Suzumiya, MD PhD, Koji Izutsu, MD PhD, Momoko Nishikori, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD PhD, Kenichi Yoshimura, PhD, Ukihide Tateishi, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tsutomu Takahashi, MD PhD, Takahiro Yamauchi, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2019) 134 (Supplement_1): 5245.

DOI: https://doi.org/10.1182/blood-2019-126455

Published: 2019

Journal Articles

Prospective Comparison of Azacitidine Treatment between 7-Days and 5-Days Schedules for Patients with Higher-Risk Myelodysplastic Syndromes; Results of Japan Adult Leukemia Study Group MDS212 Trial

Blood (2019) 134 (Supplement_1): 845.

DOI: https://doi.org/10.1182/blood-2019-122802

Published: 2019

Journal Articles

The Effect of Diagnostic Wait Time on the Survival of Patients with Diffuse Large B-Cell Lymphoma Differs Depending on International Prognostic Index

Shin Lee, MD, Negoro Eiju, Morishita Tetsuji, MD PhD, Kei Fujita, MD, Hideaki Yamauchi, MD, Kana Oiwa, MD, Takanori Ueda, MD PhD, Takahiro Yamauchi, MD PhD

Blood (2019) 134 (Supplement_1): 2902.

DOI: https://doi.org/10.1182/blood-2019-121527

Published: 2019

Journal Articles

Pralatrexate-Resistant Cell Lines Show Intact Internalization Via RFC1 but Collateral Sensitivity to Nucleoside Analogs

Kana Oiwa, MD, Naoko Hosono, MD, Rie Nishi, PhD, Takanori Ueda, MD PhD, Luigi Scott, PhD, Owen A. O'Connor, MD, PhD, Takahiro Yamauchi, MD PhD

Blood (2018) 132 (Supplement 1): 3961.

DOI: https://doi.org/10.1182/blood-2018-99-110147

Published: 2018

Journal Articles

Malignant Progression of an MDS-Derived Cell Line Serves As an in Vitro Model for the Leukemic Evolution of MDS

Jun-ichiro Kida, MD, Takayuki Tsujioka, MD, Shin-ichiro Suemori, MD, Shuichiro Okamoto, MD, Kanae Sakakibara, Takahiro Yamauchi, MD PhD, Akira Kitanaka, MD, Yumi Tohyama, PhD, Kaoru Tohyama, MD

Blood (2018) 132 (Supplement 1): 5501.

DOI: https://doi.org/10.1182/blood-2018-99-110583

Published: 2018

Journal Articles

Updated Report of a Phase I/II Multicenter Study of Forodesine, a Purine Nucleoside Phosphorylase Inhibitor, in Japanese Patients with Relapsed Peripheral T-Cell Lymphoma

Blood (2017) 130 (Supplement 1): 4075.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4075.4075

Published: 2017

Journal Articles

YM155 Exerts Potent Cytotoxic Activity Against Quiescent (G0/G1) Multiple Myeloma and Bortezomib Resistant Cells Via Inhibition of Mcl-1 and Survivin

Miyuki Ookura, MD, Tatsuya Fujii, Shinji Kishi, MD PhD, Hiroko Shigemi, MDPhD, Naoko Hosono, MDPhD, Takahiro Yamauchi, MD PhD, Takanori Ueda, MD PhD, Akira Yoshida, MD PhD

Blood (2015) 126 (23): 3023.

DOI: https://doi.org/10.1182/blood.V126.23.3023.3023

Published: 2015

Journal Articles

Decitabine Induced the Cell Differentiation, Decreased Malignant Potential, and Increased Susceptibility to Apoptosis Via a Death Receptor Pathway with Hypomethylation of MS4A3, PAR-4, APITD1, LOX in Myelodysplastic Syndrome Cell Line, MDS-L

Rie Nishi, Takahiro Yamauchi, MD PhD, Miyuki Ookura, MD, Yasufumi Matsuda, MD, Toshiki Tasaki, MD, Kaoru Tohyama, MD PhD, Takanori Ueda, MD PhD

Blood (2014) 124 (21): 4599.

DOI: https://doi.org/10.1182/blood.V124.21.4599.4599

Published: 2014

Journal Articles

Synergistic Cytotoxicity Between Panobinostat and Ponatinib In Imatinib-Resistant Chronic Myeloid Leukemia Cells

Yasufumi Matsuda, MD, Takahiro Yamauchi, MD, PhD, Kanako Uzui, Eiju Negoro, MD, Koji Morinaga, MD., PhD., Hiroko Shigemi, MD, Rie Nishi, Shinya Kimura, MD, PhD, Taira Maekawa, MD, PhD, Takanori Ueda, MD, PhD

Blood (2013) 122 (21): 3989.

DOI: https://doi.org/10.1182/blood.V122.21.3989.3989

Published: 2013

NARROW

Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)

Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia

Genomic Analysis of NPM1 Mutation and KMT2A ( MLL )-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01

Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01

Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis

Genomic Analysis of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Combination of Highly Sensitive C-Reactive Protein with R-ISS Is a Novel and Powerful Staging System in Multiple Myeloma

Interim Analysis of Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study of Patients with AML

Genetic Features of AML with MLL-Rearrangement and NPM1 Mutation: An Interim-Analysis of HM-Screen-Japan 01

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Prospective Comparison of Azacitidine Treatment between 7-Days and 5-Days Schedules for Patients with Higher-Risk Myelodysplastic Syndromes; Results of Japan Adult Leukemia Study Group MDS212 Trial

The Effect of Diagnostic Wait Time on the Survival of Patients with Diffuse Large B-Cell Lymphoma Differs Depending on International Prognostic Index

Pralatrexate-Resistant Cell Lines Show Intact Internalization Via RFC1 but Collateral Sensitivity to Nucleoside Analogs

Malignant Progression of an MDS-Derived Cell Line Serves As an in Vitro Model for the Leukemic Evolution of MDS

Updated Report of a Phase I/II Multicenter Study of Forodesine, a Purine Nucleoside Phosphorylase Inhibitor, in Japanese Patients with Relapsed Peripheral T-Cell Lymphoma

YM155 Exerts Potent Cytotoxic Activity Against Quiescent (G0/G1) Multiple Myeloma and Bortezomib Resistant Cells Via Inhibition of Mcl-1 and Survivin

Decitabine Induced the Cell Differentiation, Decreased Malignant Potential, and Increased Susceptibility to Apoptosis Via a Death Receptor Pathway with Hypomethylation of MS4A3, PAR-4, APITD1, LOX in Myelodysplastic Syndrome Cell Line, MDS-L

Synergistic Cytotoxicity Between Panobinostat and Ponatinib In Imatinib-Resistant Chronic Myeloid Leukemia Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only